{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:59:37Z","timestamp":1790492377183,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.033","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T02:27:50Z","timestamp":1615084070000},"page":"1846-1856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models"],"prefix":"10.1016","volume":"39","author":[{"given":"Fabienne","family":"Piras-Douce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Raquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Girerd-Chambaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-7829","authenticated-orcid":false,"given":"Sylviane","family":"Gautheron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Erika Navarro","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Vangelisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.033_b0005","unstructured":"World Health Organization. Yellow fever; 2019. https:\/\/www.wh.oint\/news-room\/fact-sheets\/detail\/yellow-fever [Accessed 3 February 2020]."},{"key":"10.1016\/j.vaccine.2021.02.033_b0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/trstmh\/tru092","article-title":"The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases","volume":"108","author":"Johansson","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.02.033_b0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0020","doi-asserted-by":"crossref","first-page":"e01253","DOI":"10.1128\/mBio.01253-14","article-title":"Human genetic variation and yellow fever mortality during 19th century U.S. epidemics","volume":"5","author":"Blake","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2021.02.033_b0025","unstructured":"World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013. Wkly Epidemiol Rec 2013; 88:269\u201383."},{"key":"10.1016\/j.vaccine.2021.02.033_b0030","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.033_b0035","unstructured":"SAGE Working Group. Background Paper on Yellow Fever Vaccine; 2013. Available at: https:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/april\/1_Background_Paper_Yellow_Fever_Vaccines.pdf [Accessed 3 Februrary 2020]."},{"key":"10.1016\/j.vaccine.2021.02.033_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2021.02.033_b0045","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.033_b0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/CVI.00369-09","article-title":"Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination","volume":"17","author":"Silva","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0055","unstructured":"UNICEF. Yellow Fever Vaccine: Current Supply Outlook; 2016. Available at: https:\/\/www.unicef.org\/supply\/files\/YF_number_3_Supply_Update.pdf [Accessed 3 Februrary 2020]."},{"key":"10.1016\/j.vaccine.2021.02.033_b0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/vaccines7040179","article-title":"Disease resurgence, production capability issues and safety concerns in the context of an aging population: Is there a need for a new yellow fever vaccine?","volume":"7","author":"Tomashek","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.033_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188333","article-title":"A universal mammalian vaccine cell line substrate","volume":"12","author":"Murray","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.033_b0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.033_b0075","doi-asserted-by":"crossref","DOI":"10.4161\/hv.6.9.12739","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine","volume":"6","author":"Guy","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2021.02.033_b0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.02.033_b0085","article-title":"Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium","volume":"6","author":"Hu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.033_b0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coviro.2016.03.010","article-title":"Animal models of yellow fever and their application in clinical research","volume":"18","author":"Julander","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000614","article-title":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection","volume":"5","author":"Meier","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.02.033_b0100","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/vir.0.000075","article-title":"Spectrum of disease outcomes in mice infected with YFV-17D","volume":"96","author":"Erickson","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0105","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.033_b0110","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.033_b0115","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejpb.2019.07.008","article-title":"A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate","volume":"142","author":"Clenet","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2021.02.033_b0120","unstructured":"World Health Organization. Requirments for yellow fever vaccine, Annex 2; 1998. Available at: https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/yellow_fever\/en\/ [Accessed 5 Februrary 2020]."},{"key":"10.1016\/j.vaccine.2021.02.033_b0125","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.vaccine.2006.06.082","article-title":"High stability of yellow fever 17D\u2013204 vaccine: a 12-year restrospective analysis of large-scale production","volume":"25","author":"Barban","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.033_b0130","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.02.033_b0135","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/14760584.2015.1083430","article-title":"Current status and future prospects of yellow fever vaccines","volume":"14","author":"Beck","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.033_b0140","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01836-16","article-title":"Mutagenesis of dengue virus protein NS2A revealed a novel domain responsible for virus-induced cytopathic effect and interactions between NS2A and NS2B transmembrane segments","volume":"91","author":"Wu","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.02.033_b0150","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760190187","article-title":"Generation of Yellow Fever virus vaccine in skeletal muscle cells of chicken embryos","volume":"114","author":"Souza","year":"2019","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2021.02.033_b0155","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.vaccine.2004.10.035","article-title":"Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity","volume":"23","author":"Freire","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.033_b0160","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:39Z","timestamp":1759402479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21002000"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.033","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/M1PCGV","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}